PHILADELPHIA — GSK has started shipping its quadrivalent influenza vaccines to U.S. health care providers and pharmacies for the 2021-22 flu season. This immediately follows a licensing and lot-release approval from the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. GSK expects to distribute more doses than it has in any
NEW YORK— GlaxoSmithKline and CureVac N.V have announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. GSK will also support the manufacture of up to 100 million doses of CureVac’s
BURLINGAME, Calif. — Ten of the world’s leading biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a
NEW YORK — A provision in the Coronavirus Aid, Relief and Economic Security (CARES) Act, which Congress passed and President Trump signed into law in March, offers a potential boon to consumers and retailers, according to GlaxoSmithKline (GSK), which is one of the largest providers of over-the-counter medications in the world. The provision in the
PHILADELPHIA — GlaxoSmithKline has started shipping its quadrivalent influenza vaccines to US health care providers and pharmacies for the 2020-21 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. “The flu is a serious and unpredictable disease that causes tens
LONDON — GSK has confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates. GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19. As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can
WARREN, N.J.— GlaxoSmithKline recently announced a multi-year partnership with the Arthritis Foundation to support scientific research, advocacy as well as virtual resources and community connections for the more than 30 million people in America living with osteoarthritis (OA). As part of the mission for an osteoarthritis cure, Voltaren Arthritis Pain is donating 100% of profits
PHILADELPHIA — GlaxoSmithKline (GSK) today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2018-19 flu season, immediately following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. The U.S. Centers for Disease Control and Prevention (CDC) estimates that
MINNEAPOLIS — UnitedHealth Group has tapped former GlaxoSmithKline PLC (GSK) chief executive officer Sir Andrew Witty as the next CEO of Optum, its health services, technology and pharmacy benefits management unit. The appointment is effective July 1. Witty, 53, will succeed Larry Renfro, who is set to lead UnitedHealth Group’s enterprise growth efforts and Optum’s
WARREN, N.J. — One of the world’s largest consumer health care companies celebrated the grand opening of its new state-of-the-art headquarters here earlier this month with company leaders and federal, state and local dignitaries. GlaxoSmithKline Consumer Healthcare — known for such brands as Sensodyne, Theraflu, Excedrin, Nicorette and NicoDermCQ, Flonase, and TUMS — held the
LONDON — Sir Andrew Witty, chief executive officer of GlaxoSmithKline plc, plans to retire from the company next year. GSK announced Witty’s retirement Thursday in releasing its 2015 annual report to shareholders. Plans call for Witty to step down from the CEO post on March 31, 2017. The board of directors plans to conduct a